15 results
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... #Endometrial #Biliary ... #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
Algorithm for the Evaluation of Anemia #Diagnosis #EM #IM #Honc #Anemia #Differential #Workup #Algorithm #Microcytic #Macrocytic
Algorithm for the ... Anemia #Diagnosis #EM ... #IM #Honc #Anemia ... Differential #Workup #Algorithm
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Generalized #Diagnosis #EM ... #IM #Honc #Lymphadenopathy ... #Differential #Algorithm
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
of Progression #EBM ... #Honc #MGUS #Progression ... MultipleMyeloma #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... VisualAbstract #NEJM
Causes of Acute Liver Injury - Differential Diagnosis
Hepatocellular - Liver Parenchyma
 • Infectious: Hepatitis C, A,
C, A, E, B, D, EBV ... hepatitis, Acute biliary ... Extrahepatic • Biliary ... Causes #Acute #algorithm
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... Durvalumab #NSCLC #NEJM